AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. IXHL
  4. [8-K] Incannex Healthcare Limited American Reports Material Event

[8-K] Incannex Healthcare Limited American Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Incannex Healthcare (NASDAQ: IXHL), an emerging growth company, announced the appointment of Dr. Douglas B. Kirsch to its Clinical Advisory Board on June 24, 2025, specifically to support its Obstructive Sleep Apnea program.

Key details from the 8-K filing:

  • The company is listed on The Nasdaq Stock Market with common stock at $0.0001 par value per share
  • Headquartered in Norwest, NSW, Australia
  • Joel Latham serves as Chief Executive Officer and President
  • The company has elected emerging growth company status
  • The appointment represents a strategic expansion of expertise in sleep medicine, potentially strengthening the company's clinical development programs

This strategic addition to the advisory board signals Incannex's continued focus on advancing its sleep apnea therapeutic programs and enhancing its clinical development capabilities.

Incannex Healthcare (NASDAQ: IXHL), un'azienda in crescita emergente, ha annunciato il nomina del Dott. Douglas B. Kirsch al suo Clinical Advisory Board il 24 giugno 2025, con l'obiettivo specifico di supportare il programma per l'Apnea Ostruttiva del Sonno.

Dettagli chiave dal documento 8-K:

  • L'azienda 猫 quotata al Nasdaq Stock Market con azioni ordinarie dal valore nominale di $0,0001 per azione
  • Ha sede a Norwest, NSW, Australia
  • Joel Latham ricopre il ruolo di Amministratore Delegato e Presidente
  • L'azienda ha scelto lo status di societ脿 in crescita emergente
  • La nomina rappresenta un'espansione strategica delle competenze nella medicina del sonno, rafforzando potenzialmente i programmi di sviluppo clinico dell'azienda

Questa aggiunta strategica al consiglio consultivo evidenzia il continuo impegno di Incannex nel potenziare i suoi programmi terapeutici per l'apnea del sonno e nel migliorare le sue capacit脿 di sviluppo clinico.

Incannex Healthcare (NASDAQ: IXHL), una empresa en crecimiento emergente, anunci贸 el nombramiento del Dr. Douglas B. Kirsch en su Consejo Asesor Cl铆nico el 24 de junio de 2025, espec铆ficamente para apoyar su programa de Apnea Obstructiva del Sue帽o.

Detalles clave del informe 8-K:

  • La empresa cotiza en el Nasdaq Stock Market con acciones comunes con un valor nominal de $0.0001 por acci贸n
  • Con sede en Norwest, NSW, Australia
  • Joel Latham es el Director Ejecutivo y Presidente
  • La empresa ha elegido el estatus de empresa en crecimiento emergente
  • El nombramiento representa una expansi贸n estrat茅gica de la experiencia en medicina del sue帽o, fortaleciendo potencialmente los programas de desarrollo cl铆nico de la empresa

Esta incorporaci贸n estrat茅gica al consejo asesor se帽ala el continuo enfoque de Incannex en avanzar sus programas terap茅uticos para la apnea del sue帽o y mejorar sus capacidades de desarrollo cl铆nico.

Incannex Healthcare (NASDAQ: IXHL), 鞁犿潵 靹膘灔 旮办梾鞙茧靹�, 2025雲� 6鞗� 24鞚检棎 鞛勳儊 鞛愲 鞙勳洂須岇棎 Douglas B. Kirsch 氚曥偓毳� 鞛勲獏頄堧嫟瓿� 氚滍憸頄堨溂氅�, 韸鬼瀳 韽愳噭靹� 靾橂┐ 氍错樃頋§ 頂勲攴鸽灗 歆�鞗愳潉 鞙勴暣靹滌瀰雼堧嫟.

8-K 氤搓碃靹滌潣 欤检殧 雮挫毄:

  • 須岇偓電� 氤错喌欤� 鞎‰┐臧� $0.0001搿� 雮橃姢雼� 欤检嫕鞁滌灔鞐� 靸侅灔霅橃柎 鞛堨潓
  • 氤胳偓電� 順胳＜ NSW欤� 雲胳姢鞗姢韸胳棎 鞙勳箻
  • Joel Latham鞚� 斓滉碃瓴届榿鞛�(CEO) 瓴� 靷灔鞙茧 鞛 欷�
  • 須岇偓電� 鞁犿潵 靹膘灔 旮办梾 歆�鞙勲ゼ 靹犿儩頃�
  • 鞚措矆 鞛勲獏鞚� 靾橂┐ 鞚橅暀 攵勳暭 鞝勲靹膘潣 鞝勲灥鞝� 頇曥灔鞙茧, 須岇偓鞚� 鞛勳儊 臧滊皽 頂勲攴鸽灗鞚� 臧曧檾頃� 臧�電レ劚鞚� 鞛堨潓

鞚� 鞝勲灥鞝� 鞛愲鞙勳洂須� 於旉皜電� Incannex臧� 靾橂┐ 氍错樃頋� 旃橂 頂勲攴鸽灗鞚� 氚滌爠鞁滍偆瓿� 鞛勳儊 臧滊皽 鞐焿鞚� 臧曧檾頃橂姅 雿� 歆�靻嶌爜鞙茧 歆戩頃橁碃 鞛堨潓鞚� 雮橅儉雰呺媹雼�.

Incannex Healthcare (NASDAQ : IXHL), une entreprise en croissance 茅mergente, a annonc茅 le nomination du Dr Douglas B. Kirsch 脿 son conseil consultatif clinique le 24 juin 2025, sp茅cifiquement pour soutenir son programme d'apn茅e obstructive du sommeil.

Points cl茅s du d茅p么t 8-K :

  • L'entreprise est cot茅e au Nasdaq Stock Market avec des actions ordinaires d'une valeur nominale de 0,0001 $ par action
  • Si猫ge social situ茅 脿 Norwest, NSW, Australie
  • Joel Latham occupe les fonctions de directeur g茅n茅ral et pr茅sident
  • L'entreprise a choisi le statut d'entreprise en croissance 茅mergente
  • Cette nomination repr茅sente une expansion strat茅gique de l'expertise en m茅decine du sommeil, renfor莽ant potentiellement les programmes de d茅veloppement clinique de l'entreprise

Cette addition strat茅gique au conseil consultatif souligne l'engagement continu d'Incannex 脿 faire progresser ses programmes th茅rapeutiques pour l'apn茅e du sommeil et 脿 am茅liorer ses capacit茅s de d茅veloppement clinique.

Incannex Healthcare (NASDAQ: IXHL), ein aufstrebendes Wachstumsunternehmen, gab am 24. Juni 2025 die Ernennung von Dr. Douglas B. Kirsch in seinen Clinical Advisory Board bekannt, speziell zur Unterst眉tzung seines Programms zur obstruktiven Schlafapnoe.

Wichtige Details aus der 8-K-Meldung:

  • Das Unternehmen ist an der Nasdaq Stock Market mit Stammaktien zum Nennwert von 0,0001 USD pro Aktie gelistet
  • Der Hauptsitz befindet sich in Norwest, NSW, Australien
  • Joel Latham ist Gesch盲ftsf眉hrer und Pr盲sident
  • Das Unternehmen hat den Status eines Emerging Growth Company gew盲hlt
  • Die Ernennung stellt eine strategische Erweiterung der Expertise in der Schlafmedizin dar und k枚nnte die klinischen Entwicklungsprogramme des Unternehmens st盲rken

Diese strategische Erg盲nzung des Beratungsgremiums signalisiert Incannex' fortgesetzten Fokus auf die Weiterentwicklung seiner Therapieprogramme f眉r Schlafapnoe und die Verbesserung seiner klinischen Entwicklungskapazit盲ten.

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

Incannex Healthcare (NASDAQ: IXHL), un'azienda in crescita emergente, ha annunciato il nomina del Dott. Douglas B. Kirsch al suo Clinical Advisory Board il 24 giugno 2025, con l'obiettivo specifico di supportare il programma per l'Apnea Ostruttiva del Sonno.

Dettagli chiave dal documento 8-K:

  • L'azienda 猫 quotata al Nasdaq Stock Market con azioni ordinarie dal valore nominale di $0,0001 per azione
  • Ha sede a Norwest, NSW, Australia
  • Joel Latham ricopre il ruolo di Amministratore Delegato e Presidente
  • L'azienda ha scelto lo status di societ脿 in crescita emergente
  • La nomina rappresenta un'espansione strategica delle competenze nella medicina del sonno, rafforzando potenzialmente i programmi di sviluppo clinico dell'azienda

Questa aggiunta strategica al consiglio consultivo evidenzia il continuo impegno di Incannex nel potenziare i suoi programmi terapeutici per l'apnea del sonno e nel migliorare le sue capacit脿 di sviluppo clinico.

Incannex Healthcare (NASDAQ: IXHL), una empresa en crecimiento emergente, anunci贸 el nombramiento del Dr. Douglas B. Kirsch en su Consejo Asesor Cl铆nico el 24 de junio de 2025, espec铆ficamente para apoyar su programa de Apnea Obstructiva del Sue帽o.

Detalles clave del informe 8-K:

  • La empresa cotiza en el Nasdaq Stock Market con acciones comunes con un valor nominal de $0.0001 por acci贸n
  • Con sede en Norwest, NSW, Australia
  • Joel Latham es el Director Ejecutivo y Presidente
  • La empresa ha elegido el estatus de empresa en crecimiento emergente
  • El nombramiento representa una expansi贸n estrat茅gica de la experiencia en medicina del sue帽o, fortaleciendo potencialmente los programas de desarrollo cl铆nico de la empresa

Esta incorporaci贸n estrat茅gica al consejo asesor se帽ala el continuo enfoque de Incannex en avanzar sus programas terap茅uticos para la apnea del sue帽o y mejorar sus capacidades de desarrollo cl铆nico.

Incannex Healthcare (NASDAQ: IXHL), 鞁犿潵 靹膘灔 旮办梾鞙茧靹�, 2025雲� 6鞗� 24鞚检棎 鞛勳儊 鞛愲 鞙勳洂須岇棎 Douglas B. Kirsch 氚曥偓毳� 鞛勲獏頄堧嫟瓿� 氚滍憸頄堨溂氅�, 韸鬼瀳 韽愳噭靹� 靾橂┐ 氍错樃頋§ 頂勲攴鸽灗 歆�鞗愳潉 鞙勴暣靹滌瀰雼堧嫟.

8-K 氤搓碃靹滌潣 欤检殧 雮挫毄:

  • 須岇偓電� 氤错喌欤� 鞎‰┐臧� $0.0001搿� 雮橃姢雼� 欤检嫕鞁滌灔鞐� 靸侅灔霅橃柎 鞛堨潓
  • 氤胳偓電� 順胳＜ NSW欤� 雲胳姢鞗姢韸胳棎 鞙勳箻
  • Joel Latham鞚� 斓滉碃瓴届榿鞛�(CEO) 瓴� 靷灔鞙茧 鞛 欷�
  • 須岇偓電� 鞁犿潵 靹膘灔 旮办梾 歆�鞙勲ゼ 靹犿儩頃�
  • 鞚措矆 鞛勲獏鞚� 靾橂┐ 鞚橅暀 攵勳暭 鞝勲靹膘潣 鞝勲灥鞝� 頇曥灔鞙茧, 須岇偓鞚� 鞛勳儊 臧滊皽 頂勲攴鸽灗鞚� 臧曧檾頃� 臧�電レ劚鞚� 鞛堨潓

鞚� 鞝勲灥鞝� 鞛愲鞙勳洂須� 於旉皜電� Incannex臧� 靾橂┐ 氍错樃頋� 旃橂 頂勲攴鸽灗鞚� 氚滌爠鞁滍偆瓿� 鞛勳儊 臧滊皽 鞐焿鞚� 臧曧檾頃橂姅 雿� 歆�靻嶌爜鞙茧 歆戩頃橁碃 鞛堨潓鞚� 雮橅儉雰呺媹雼�.

Incannex Healthcare (NASDAQ : IXHL), une entreprise en croissance 茅mergente, a annonc茅 le nomination du Dr Douglas B. Kirsch 脿 son conseil consultatif clinique le 24 juin 2025, sp茅cifiquement pour soutenir son programme d'apn茅e obstructive du sommeil.

Points cl茅s du d茅p么t 8-K :

  • L'entreprise est cot茅e au Nasdaq Stock Market avec des actions ordinaires d'une valeur nominale de 0,0001 $ par action
  • Si猫ge social situ茅 脿 Norwest, NSW, Australie
  • Joel Latham occupe les fonctions de directeur g茅n茅ral et pr茅sident
  • L'entreprise a choisi le statut d'entreprise en croissance 茅mergente
  • Cette nomination repr茅sente une expansion strat茅gique de l'expertise en m茅decine du sommeil, renfor莽ant potentiellement les programmes de d茅veloppement clinique de l'entreprise

Cette addition strat茅gique au conseil consultatif souligne l'engagement continu d'Incannex 脿 faire progresser ses programmes th茅rapeutiques pour l'apn茅e du sommeil et 脿 am茅liorer ses capacit茅s de d茅veloppement clinique.

Incannex Healthcare (NASDAQ: IXHL), ein aufstrebendes Wachstumsunternehmen, gab am 24. Juni 2025 die Ernennung von Dr. Douglas B. Kirsch in seinen Clinical Advisory Board bekannt, speziell zur Unterst眉tzung seines Programms zur obstruktiven Schlafapnoe.

Wichtige Details aus der 8-K-Meldung:

  • Das Unternehmen ist an der Nasdaq Stock Market mit Stammaktien zum Nennwert von 0,0001 USD pro Aktie gelistet
  • Der Hauptsitz befindet sich in Norwest, NSW, Australien
  • Joel Latham ist Gesch盲ftsf眉hrer und Pr盲sident
  • Das Unternehmen hat den Status eines Emerging Growth Company gew盲hlt
  • Die Ernennung stellt eine strategische Erweiterung der Expertise in der Schlafmedizin dar und k枚nnte die klinischen Entwicklungsprogramme des Unternehmens st盲rken

Diese strategische Erg盲nzung des Beratungsgremiums signalisiert Incannex' fortgesetzten Fokus auf die Weiterentwicklung seiner Therapieprogramme f眉r Schlafapnoe und die Verbesserung seiner klinischen Entwicklungskapazit盲ten.

false 0001873875 0001873875 2025-06-24 2025-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

  

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 24, 2025

 

Incannex Healthcare Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41106   93-2403210

(State or other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

Suite 105, 8 Century Circuit Norwest,

NSW 2153 Australia

   Not applicable
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s Telephone Number, including Area Code: +61 409 840 786

 

(Former Name or Former Address, if Changed Since Last Report): Not Applicable

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of exchange on which registered
Common Stock, $0.0001 par value per share   IXHL   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

  

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 8.01 Other Events.

 

On June 24, 2025, Incannex Healthcare Inc. Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch. Further information is included in the press release attached as Exhibit 99.1 hereto, which is incorporated by reference into this Item 8.01.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release of Incannex Healthcare Inc., dated June 24, 2025.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Incannex Healthcare Inc.
     
Date: June 24, 2025   /s/ Joel Latham
  Name:  Joel Latham
  Title: Chief Executive Officer and President

 

2

 

Source:

FAQ

Why did IXHL file an 8-K on June 24, 2025?

IXHL filed an 8-K to announce the expansion of its Clinical Advisory Board with the appointment of Dr. Douglas B. Kirsch to support their Obstructive Sleep Apnea Program.

Who is the new appointee to IXHL's Clinical Advisory Board?

Dr. Douglas B. Kirsch was appointed to IXHL's Clinical Advisory Board to support the company's Obstructive Sleep Apnea Program, as announced on June 24, 2025.

Who is the current CEO of IXHL?

Joel Latham serves as the Chief Executive Officer and President of Incannex Healthcare Inc. (IXHL), as evidenced by his signature on the 8-K filing dated June 24, 2025.

Is IXHL considered an emerging growth company?

Yes, IXHL is classified as an emerging growth company as indicated by the checked box in the 8-K filing. The company has not elected to use the extended transition period for complying with new financial accounting standards.

Where is IXHL's principal executive office located?

IXHL's principal executive office is located at Suite 105, 8 Century Circuit Norwest, NSW 2153 Australia.
Stock IXHL logo
Incannex Healthcare Ltd

NASDAQ:IXHL

IXHL Rankings

#8460 Ranked by Market Cap
N/A Ranked by Dividends

IXHL Latest News

Jul 25, 2025
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo
Jun 24, 2025
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch
Jun 18, 2025
Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X
Jun 17, 2025
Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy
Jun 12, 2025
Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

IXHL Latest SEC Filings

Jul 25, 2025
[8-K] Incannex Healthcare Limited American Reports Material Event
Jul 24, 2025
[8-K] Incannex Healthcare Limited American Reports Material Event
Jul 24, 2025
[424B5] Incannex Healthcare Limited American Prospectus Supplement (Debt Securities)

IXHL Stock Data

94.63M
21.74M
30.57%
1.25%
0.43%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Australia
NORWEST NSW